MX359384B - Conjunto mejorado de anticuerpos bisespecificos. - Google Patents

Conjunto mejorado de anticuerpos bisespecificos.

Info

Publication number
MX359384B
MX359384B MX2014004322A MX2014004322A MX359384B MX 359384 B MX359384 B MX 359384B MX 2014004322 A MX2014004322 A MX 2014004322A MX 2014004322 A MX2014004322 A MX 2014004322A MX 359384 B MX359384 B MX 359384B
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
improved assembly
target molecule
heteromultimeric
methods
Prior art date
Application number
MX2014004322A
Other languages
English (en)
Other versions
MX2014004322A (es
Inventor
Justin Scheer
Glen Giese
Josefine Persson
Ambrose Williams
Amy Lim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2014004322A publication Critical patent/MX2014004322A/es
Publication of MX359384B publication Critical patent/MX359384B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para la producción eficiente de una proteína heteromultimérica, tal como un anticuerpo bisespecífico. Las proteínas heteromultiméricas pueden ser aptas de enlazarse específicamente a más de una molécula objetivo o epítopos diferentes en una sola molécula objetivo. Los métodos modulan parámetros para mejorar el ensamble de las proteínas heteromultiméricas a un rendimiento más alto y eficiencia más alta que de otra manera son posibles. También se describen composiciones que comprenden un polipéptido que contiee bizagra, tal como un semi-anticuerpo.
MX2014004322A 2011-10-11 2012-10-11 Conjunto mejorado de anticuerpos bisespecificos. MX359384B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161545863P 2011-10-11 2011-10-11
US201161546503P 2011-10-12 2011-10-12
US201161560704P 2011-11-16 2011-11-16
US201261676837P 2012-07-27 2012-07-27
PCT/US2012/059810 WO2013055958A1 (en) 2011-10-11 2012-10-11 Improved assembly of bispecific antibodies

Publications (2)

Publication Number Publication Date
MX2014004322A MX2014004322A (es) 2014-07-28
MX359384B true MX359384B (es) 2018-09-25

Family

ID=47073551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004322A MX359384B (es) 2011-10-11 2012-10-11 Conjunto mejorado de anticuerpos bisespecificos.

Country Status (17)

Country Link
US (4) US9862778B2 (es)
EP (2) EP3418306B1 (es)
JP (1) JP6216321B2 (es)
KR (3) KR102106002B1 (es)
CN (2) CN104093744A (es)
BR (1) BR112014008684B1 (es)
CA (1) CA2850818A1 (es)
ES (2) ES2682081T3 (es)
HK (1) HK1202878A1 (es)
HR (2) HRP20240230T1 (es)
HU (1) HUE065876T2 (es)
MX (1) MX359384B (es)
PL (2) PL2766397T3 (es)
RU (1) RU2654567C2 (es)
SI (1) SI2766397T1 (es)
TR (1) TR201809151T4 (es)
WO (1) WO2013055958A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0711282B2 (ja) 1990-02-23 1995-02-08 シーケーデイ株式会社 ロツドレスシリンダ
JPH07111203B2 (ja) 1991-09-06 1995-11-29 エスエムシー株式会社 ロッドレスシリンダ
DE4137789C2 (de) 1991-11-16 1994-01-20 Festo Kg Linearantrieb
CN104093744A (zh) * 2011-10-11 2014-10-08 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
EP2970422B1 (en) 2013-03-15 2018-04-18 F.Hoffmann-La Roche Ag Il-22 polypeptides and il-22 fc fusion proteins and methods of use
JP2016520595A (ja) * 2013-05-22 2016-07-14 メタボリック エンジニアリング ラボラトリーズ カンパニー リミテッド 抗ＴＮＦ−α／ＣＸＣＬ１０二重ターゲット抗体及びその用途
US10370776B2 (en) * 2013-09-25 2019-08-06 Idea Orchard, Llc Antibody like protein
PT3074424T (pt) 2013-11-27 2025-05-29 Zymeworks Bc Inc Construções de ligação a antigénio biespecíficas direcionadas a her2
CN106029693A (zh) 2014-02-21 2016-10-12 豪夫迈·罗氏有限公司 抗il-13/il-17双特异性抗体及其用途
HUE063273T2 (hu) 2014-05-06 2024-01-28 Hoffmann La Roche Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
CN104195173B (zh) * 2014-09-02 2017-03-08 北京比洋生物技术有限公司 具有双表达盒的谷氨酰胺合成酶高效表达载体
CA2966558C (en) 2014-11-05 2024-03-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
AU2015342964B2 (en) 2014-11-05 2021-06-24 Genentech, Inc. Methods of producing two chain proteins in bacteria
DK3223848T3 (da) 2014-11-27 2025-03-03 Zymeworks Bc Inc Fremgangsmåder til anvendelse af bispecifikke antigenbindingskonstrukter målrettet her2
WO2016146594A1 (en) * 2015-03-13 2016-09-22 Novimmune Sa Methods of purifying bispecific antibodies
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR102095096B1 (ko) 2015-08-26 2020-03-30 바이슨 테라퓨틱스 인크. 다중특이적 항체 플랫폼 및 관련 방법
CN108602884B (zh) 2015-11-08 2024-06-25 豪夫迈·罗氏有限公司 筛选多特异性抗体的方法
ES2988363T3 (es) 2016-06-17 2024-11-20 Hoffmann La Roche Purificación de anticuerpos multiespecíficos
WO2018050873A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
CN109982716B (zh) * 2016-09-16 2024-05-10 白血球保健股份有限公司 在加工过程中稳定生物制药药物产品的新方法
JP7051132B2 (ja) 2016-09-16 2022-04-11 ロイコケア・アクチェンゲゼルシャフト ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
JP7227146B2 (ja) 2016-11-23 2023-02-21 バイオベラティブ セラピューティクス インコーポレイテッド 凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体
TW201834688A (zh) * 2017-02-24 2018-10-01 日商中外製藥股份有限公司 藥學組成物、抗原結合分子、治療方法以及篩選方法
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
MX420947B (es) 2017-04-26 2025-02-10 Eureka Therapeutics Inc Constructos que reconocen específicamente glipicano 3 y usos de estos.
MX2019012381A (es) * 2017-05-18 2020-01-23 Hoffmann La Roche Reduccion de reaccion secundaria relacionada con la aplicacion de un anticuerpo terapeutico.
EP3710482A4 (en) 2017-11-14 2021-08-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
EP3818085A4 (en) 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN113286824A (zh) 2018-08-03 2021-08-20 中外制药株式会社 包含两个彼此连接的抗原结合结构域的抗原结合分子
EP3856789A4 (en) 2018-09-28 2022-08-17 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH VARIABLE REGION OF AN ALTERED ANTIBODY
EP3860567A4 (en) * 2018-10-01 2022-07-06 Amgen Inc. METHOD OF REDUCING AGGREGATION OF BISPECIFIC ANTIBODIES
KR20210111242A (ko) 2018-10-29 2021-09-10 바이오젠 엠에이 인코포레이티드 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체
EP3877407B1 (en) 2018-11-05 2026-03-11 F. Hoffmann-La Roche AG Methods of producing two chain proteins in prokaryotic host cells
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
CA3132275A1 (en) * 2019-04-25 2020-10-29 Ulrich Brinkmann Generation of antibody-derived polypeptides by polypeptide chain exchange
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
WO2020243479A1 (en) * 2019-05-31 2020-12-03 The Johns Hopkins University Bispecific binding agents
US20220251222A1 (en) * 2019-05-31 2022-08-11 The Johns Hopkins University IL-6Ralpha/IL-8R BISPECIFIC BINDING AGENTS FOR INHIBITING CANCER CELL MIGRATION
BR112022004995A2 (pt) 2019-09-18 2022-06-21 Lamkap Bio Alpha AG Anticorpos biespecíficos contra ceacam5 e cd3
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
US20230250156A1 (en) * 2020-03-22 2023-08-10 Quadrucept Bio Limited Multimers for viral strain evolution
CN115335410A (zh) * 2020-03-31 2022-11-11 中外制药株式会社 生产多特异性抗原结合分子的方法
TWI799824B (zh) 2020-03-31 2023-04-21 日商中外製藥股份有限公司 Ｄｌｌ３靶向之多特異性抗原結合分子及其用途
CN111748527B (zh) * 2020-05-15 2021-01-29 上海多宁生物科技有限公司 化学成分限定高效补料培养基及其制备方法和应用
AU2021362007A1 (en) 2020-10-16 2023-06-22 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
CN114539417A (zh) * 2020-11-26 2022-05-27 盛禾(中国)生物制药有限公司 一种有效去除双特异性抗体同源二聚体的层析纯化工艺
EP4255926A1 (en) 2020-12-07 2023-10-11 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
CA3256034A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
JP2025512512A (ja) 2022-04-14 2025-04-17 インビジシールド テクノロジーズ リミテッド コロナウイルス感染症の予防又は治療のための組成物
WO2025088516A1 (en) * 2023-10-26 2025-05-01 Pfizer Inc. Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US5292668A (en) 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
JP2665353B2 (ja) * 1988-09-10 1997-10-22 住商ファーマインターナショナル株式会社 双特異性抗体の製造法
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5789229A (en) 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
JP4516719B2 (ja) 2001-05-11 2010-08-04 アムジエン・インコーポレーテツド Ｔａｌｌ−１と結合するペプチド及び関連分子
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US6731168B2 (en) * 2002-02-06 2004-05-04 Intersil Americas, Inc. Power amplifier linearizer that compensates for long-time-constant memory effects and method therefor
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
CN1268761C (zh) * 2002-08-29 2006-08-09 上海凯曼生物科技有限公司 一种制备人载脂蛋白基因重组蛋白的方法
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
AU2004230670B2 (en) * 2003-01-09 2010-11-25 Genentech, Inc. Purification of polypeptides
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
AU2005282700A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2005282720B2 (en) 2004-09-02 2011-08-04 Genentech, Inc. Anti-FC-gamma RIIB receptor antibody and uses therefor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070274985A1 (en) * 2006-05-26 2007-11-29 Stefan Dubel Antibody
EP2035456A1 (en) * 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US8557446B2 (en) 2006-08-14 2013-10-15 Enerize Corporation Proton-conducting polyamide polymer membrane and method for production
CL2007002615A1 (es) 2006-09-08 2008-04-18 Wyeth Corp Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
EP2139924B1 (en) * 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
KR20100021601A (ko) * 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
DE102008048942B4 (de) 2008-09-25 2011-01-13 Siemens Aktiengesellschaft Anordnung mit einer Wellendichtung
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011034605A2 (en) * 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US20120259099A1 (en) 2009-12-15 2012-10-11 MuHyeon CHOE Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
CA2784278C (en) 2009-12-18 2019-02-26 Novartis Ag Wash solution and method for affinity chromatography
PL2560993T3 (pl) * 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
CA2797016A1 (en) 2010-04-22 2011-10-27 Senesco Technologies, Inc. Transgenic algae with enhanced oil expression
US9637557B2 (en) 2010-04-23 2017-05-02 Genentech, Inc. Production of heteromultimeric proteins
CA2797981C (en) * 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN104093744A (zh) * 2011-10-11 2014-10-08 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装

Also Published As

Publication number Publication date
HK1200844A1 (en) 2015-08-14
KR102492792B1 (ko) 2023-01-30
MX2014004322A (es) 2014-07-28
HRP20240230T1 (hr) 2024-04-26
CN107266577B (zh) 2022-09-13
RU2014118743A (ru) 2015-11-20
WO2013055958A1 (en) 2013-04-18
HK1202878A1 (en) 2015-10-09
KR102219217B1 (ko) 2021-02-23
HRP20181189T1 (hr) 2018-10-05
US11725065B2 (en) 2023-08-15
PL3418306T3 (pl) 2024-04-15
US9862778B2 (en) 2018-01-09
EP3418306C0 (en) 2023-12-06
CN104093744A (zh) 2014-10-08
US20240101714A1 (en) 2024-03-28
KR102106002B1 (ko) 2020-05-07
US20180162955A1 (en) 2018-06-14
TR201809151T4 (tr) 2018-07-23
KR20140082783A (ko) 2014-07-02
BR112014008684B1 (pt) 2021-11-09
PL2766397T3 (pl) 2018-10-31
EP2766397B1 (en) 2018-05-30
US10626189B2 (en) 2020-04-21
KR20200046129A (ko) 2020-05-06
US20200317820A1 (en) 2020-10-08
CA2850818A1 (en) 2013-04-18
ES2682081T3 (es) 2018-09-18
JP2014534198A (ja) 2014-12-18
JP6216321B2 (ja) 2017-10-18
HUE065876T2 (hu) 2024-06-28
US20140336361A1 (en) 2014-11-13
SI2766397T1 (sl) 2018-09-28
ES2971444T3 (es) 2024-06-05
EP3418306B1 (en) 2023-12-06
BR112014008684A2 (pt) 2019-10-15
EP2766397A1 (en) 2014-08-20
EP3418306A1 (en) 2018-12-26
RU2654567C2 (ru) 2018-05-21
KR20210021595A (ko) 2021-02-26
CN107266577A (zh) 2017-10-20

Similar Documents

Publication Publication Date Title
MX359384B (es) Conjunto mejorado de anticuerpos bisespecificos.
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
MX355255B (es) Variantes de fc y métodos para su producción.
MX2012012119A (es) Produccion de proteinas heteromultimericas.
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
WO2013188693A8 (en) Antigen binding constructs to cd3
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
WO2014143184A8 (en) Modulated lysine variant species compositions and methods for producing and using the same
MX348071B (es) Variantes de fc.
WO2013059885A3 (en) Polypeptide constructs and uses thereof
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
HK1198832A1 (en) Fn14 binding proteins and uses thereof
EA201291065A1 (ru) Антитела против vla-4
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
SG11201803989WA (en) Method for promoting efficiency of purification of fc region-containing polypeptide
WO2012125733A3 (en) Antibody screening methods
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration